InCarda Therapeutics raises $42m for inhaled atrial fibrillation drug

This article was originally published here

InCarda Therapeutics logoInCarda Therapeutics said today that it raised $42 million in an oversubscribed Series B financing round led by Sofinnova and HealthCap.

Proceeds from the round are slated to support a Phase II trial of the company’s inhaled paroxysmal atrial fibrillation drug, InRhythm.

Get the full story at our sister site, Drug Delivery Business News.

The post InCarda Therapeutics raises $42m for inhaled atrial fibrillation drug appeared first on MassDevice.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply